Anti-phosphatidylserine/prothrombin antibodies in antiphospholipid syndrome: Clinical associations and methodological heterogeneity—a scoping review
Seminars in Arthritis and Rheumatism · 2026-12 · 81 · 153105
DOI: 10.1016/j.semarthrit.2026.153105 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Arthritis and Rheumatism, 2026-12. Verfasst von H Parikh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hemato-Oncology Clinic (HOC) Vedanta, Ahmedabad, India. Die Arbeit nennt 78 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: To map the clinical and laboratory evidence for anti-phosphatidylserine/prothrombin (aPS/PT) antibodies in antiphospholipid syndrome (APS), identify the settings in which testing may add value beyond conventional antiphospholipid antibodies (aPL), and define the methodological barriers to wider clinical implementation. METHODS: We conducted a prospectively registered scoping review in accordance with PRISMA-ScR. PubMed, Embase, Scopus, and Web of Science were searched for human studies published from January 2000 onward that evaluated aPS/PT antibodies in APS or seronegative APS (SN-APS). Clinical associations, laboratory correlations, assay characteristics, cut-off definitions, titre reporting, and persistence were synthesized descriptively. RESULTS: Fifty-eight studies were included. Associations with thrombosis were evaluated in 36 studies, of which 32 reported a positive relationship. Pregnancy morbidity was assessed in 36 studies, with 21 reporting a positive association, although outcome definitions were highly variable. The most consistent laboratory finding was the association between aPS/PT and lupus anticoagulant (LA): 31 of 35 studies reported a positive relationship. Twenty-two studies included patients with SN-APS, but only six specifically examined aPS/PT in this population. Commercial assays were used in 42 studies, predominantly ELISA, yet cut-off selection, titre reporting, and confirmation of persistence varied substantially. Only 11 studies assessed persistence at least 12 weeks apart. CONCLUSIONS: aPS/PT antibodies show a reproducible clinical and laboratory signal across the APS spectrum, but their immediate value is most likely as a selective adjunct in diagnostically challenging settings rather than as a universal fourth criterion antibody. Prospective multicentre studies using harmonized assays must establish whether aPS/PT provides independent diagnostic or prognostic information beyond LA and conventional aPL profiles.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hemato-Oncology Clinic (HOC) Vedanta, Ahmedabad, India.
- Department of Medicine - DIMED, University of Padua, Padua, Italy; Internal Medicine Unit, Thrombosis and Bleeding Disorder, University Hospital of Padua, Padua, Italy.
- All India Institute of Medical Sciences (AIIMS), New Delhi, India.
- Systemic Autoimmune Diseases Unit. Department of Internal Medicine, Hospital Sant Camil, Consorci Sanitari Alt-Penedes-Garraf, Sant Pere de Ribas, Barcelona, Spain; Systemic Autoimmune Disease Research Unit. Vall d'Hebr…
- Systemic Autoimmune Disease Research Unit. Vall d'Hebron Institut de Ricerca (VHIR), Barcelona, Spain; Systemic Autoimmune Disease Unit, Department of Internal Medicine, Vall d'Hebron University Hospital, Barcelona, Spa…
- Department of Medicine - DIMED, University of Padua, Padua, Italy; Internal Medicine Unit, Thrombosis and Bleeding Disorder, University Hospital of Padua, Padua, Italy. Electronic address: ariela.hoxha@unipd.it.
Zitieren
APA
Parikh, H., Gobbo, G., Colesanti, M., Dass, J., Esteve-Valverde, E., Alijotas-Reig, J., Simioni, P., & Hoxha, A. (2026). Anti-phosphatidylserine/prothrombin antibodies in antiphospholipid syndrome: Clinical associations and methodological heterogeneity—a scoping review. Seminars in Arthritis and Rheumatism, 81, 153105. https://doi.org/10.1016/j.semarthrit.2026.153105
Vancouver
Parikh H, Gobbo G, Colesanti M, Dass J, Esteve-Valverde E, Alijotas-Reig J, et al. Anti-phosphatidylserine/prothrombin antibodies in antiphospholipid syndrome: Clinical associations and methodological heterogeneity—a scoping review. Seminars in Arthritis and Rheumatism. 2026;81:153105. doi:10.1016/j.semarthrit.2026.153105
BibTeX
@article{Parikh2026,
author = {Parikh, H and Gobbo, G and Colesanti, M and Dass, J and Esteve-Valverde, E and Alijotas-Reig, J and Simioni, P and Hoxha, A},
title = {Anti-phosphatidylserine/prothrombin antibodies in antiphospholipid syndrome: Clinical associations and methodological heterogeneity—a scoping review},
journal = {Seminars in Arthritis and Rheumatism},
year = {2026},
volume = {81},
pages = {153105},
doi = {10.1016/j.semarthrit.2026.153105}
}
EUVIMED